SAN 134

Drug Profile

SAN 134

Alternative Names: Glucagon-like peptide-2; SAN-134

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nordic Bioscience
  • Class Glucagon-like peptides
  • Mechanism of Action Bone resorption factor inhibitors; Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoporosis in Denmark (Parenteral, Injection)
  • 15 Jun 2004 Phase-I clinical trials in Osteoporosis in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top